PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

44920 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-03-31

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study. No other examinations will be performed than would have been done routinely.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diagnostic Imaging

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Drug utilization review

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Ultravist (Iopromide, BAY86-4877)

Intervention Type DRUG

Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultravist (Iopromide, BAY86-4877)

Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bayer Schering Pharma AG

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Many Locations, , Bosnia and Herzegovina

Site Status

Many Locations, , China

Site Status

Many Locations, , Germany

Site Status

Many Locations, , Hungary

Site Status

Many Locations, , Indonesia

Site Status

Many Locations, , Iran

Site Status

Many Locations, , Italy

Site Status

Many Locations, , Malaysia

Site Status

Many Locations, , Moldova

Site Status

Many Locations, , Pakistan

Site Status

Many Locations, , Philippines

Site Status

Many Locations, , Poland

Site Status

Many Locations, , Romania

Site Status

Many Locations, , Russia

Site Status

Many Locations, , Saudi Arabia

Site Status

Many Locations, , Singapore

Site Status

Many Locations, , South Korea

Site Status

Many Locations, , Taiwan

Site Status

Many Locations, , Thailand

Site Status

Many Locations, , Ukraine

Site Status

Many Locations, , Vietnam

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Bosnia and Herzegovina China Germany Hungary Indonesia Iran Italy Malaysia Moldova Pakistan Philippines Poland Romania Russia Saudi Arabia Singapore South Korea Taiwan Thailand Ukraine Vietnam